Tadalafil in the treatment of LUTS/BPH and ED

Czech version

Authors: V. Vyhnánková; D. Pacík
Published in: Urol List 2013; 11(1): 11-14

Overview

Tadalafil is one of the inhibitors of 5-phosphodiesterase PDE5, mostly used for the treatment of erectile dysfunction. The results of studies however demonstrate a positive effect on lower urinary tract symptoms associated with LUTS/BPH. In the summary of our article we want to demonstrate a common pathophysiological mechanism of ED and LUTS/BPH. The summary of the results has proven that tadalafil can be used for the treatment of LUTS/BPH and especially for patients who simultaneously have ED.

Key words:
tadalafil, erectile dysfunction, benign prostatic hyperplasia, lower urinary tract symptoms

Sources

1. Berry SJ, Coffey DS, Walsh PC et al. Development of human benign prostatic hyperplasia with age. J Urol 1984; 132(3): 474–479.

2. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342(24): 1802–1813.

3. Feldman HA, Goldsein I, Hatzichristou DG et al. Impotence and its medical psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151(1): 54–61.

4. Roehrborn CG, McVary KT, Elion-Mboussa A et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180(4): 1228–1234.

5. Gacci M, Del Popolo G, Macchiarella A et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007; 178(5): 2040–2043.

6. McVary KT. Erectile dysfunction and lower urinary trakt symtoms secundary to BPH. Eur Urol 2005; 47(6): 838–845.

7. Záleský M, Zachoval R. Tadalafil v terapii symptomů dolních močových cest u mužů. Causa Subita 2012; 15(3): 140–142.

8. McVary KT, Roehrbor CG,Kaminetski JC et al. Tedalafil relieves lower urinari tract symtoms secundari to begin prostatic hyperplasia. J Urol 2007; 177(4): 1401–1407.

9. Oelke M, Giuliano F, Mirone V et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012; 61(5): 917–925.

10. Donatucci CF, Brock GB, Goldfischer ER et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int 2011; 107(7): 1110–1116.